Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.48 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MPL | P40238 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244152 | 0.89 | TAAR1 (0.53) | NR3C2PTPN7DUSP3ARTAAR1 | |
| Hydrochloric Acid SCHEMBL3230959 | 0.87 | TAAR1 (0.52) | NR3C2PTPN7DUSP3ARTAAR1 | |
| SCHEMBL6066285 | 0.85 | DAO (0.50) | TAAR1CYP2D6CYP2C19CYP1A2KIF11 | |
| SCHEMBL81056 | 0.84 | NR3C2 (0.47) | NR3C2PTPN7DUSP3AREPHX1 | |
| SCHEMBL78124 | 0.84 | NR3C2 (0.44) | NR3C2PTPN7DUSP3AREPHX1 | |
| SCHEMBL15784581 | 0.84 | CYP1A2 (0.38) | NR3C2PTPN7DUSP3TAAR1CYP2D6 | |
| SCHEMBL41769 | 0.82 | PTPN7 (0.45) | NR3C2PTPN7DUSP3ARTAAR1 | |
| SCHEMBL19309519 | 0.81 | HTR2A (0.49) | NR3C2CYP3A4 | |
| SCHEMBL3637053 | 0.79 | NR3C2 (0.49) | NR3C2PTPN7DUSP3AREPHX1 | |
| SCHEMBL2600223 | 0.79 | CTSS (0.46) | NR3C2PTPN7DUSP3ARKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2297112-A1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| EP-2200982-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009137338-A1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009033995-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | NR3C2 275/4885PTPN7 2043/4885DUSP3 1638/4885 |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | NR3C2 275/4885PTPN7 2043/4885DUSP3 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.